Treace Medical Concepts (TMCI) Peer Comparison

$4.83

$-0.06 (-1.13%)

As on 04-Sep-2026 13:37EDT

Market cap

$299 Mln

Revenue (TTM)

$205 Mln

P/E Ratio

--

P/B Ratio

4.4

Div. Yield

0 %

Edit

	Treace Medical Concepts (TMCI)	Penumbra (PEN)	Glaukos Corp (GKOS)	Bio-Rad Laboratories	Repligen (RGEN)
Market cap ($ Mln)	299	12,650	10,638	9,762	9,948
Revenue ($ Mln)	205	1,505	613	2,589	785
Net Profit ($ Mln)	-59.52	160.59	-188.05	222.40	41.54
Net Margin (%)	-28.99	10.67	-30.68	8.59	5.29
RoE (%)	-76.76	10.86	-28.10	3.04	1.97
Price to Earnings	--	79.29	--	44.47	251.81
Price-To-Book	4.43	8.31	15.27	1.36	4.86

Income Statement
Liabilities
Assets
Cashflow
Ratios

Income Statement ($ Mln)

	Treace Medical Concepts (TMCI)	Penumbra (PEN)	Glaukos Corp (GKOS)	Bio-Rad Laboratories	Repligen (RGEN)
Operating Revenue	205.31	1,504.87	612.84	2,589.30	785.10
Cost of Revenue	42.19	483.98	127.96	1,245.50	384.30
Gross Profit	169.75	942.44	393.22	1,343.60	347.62
Operating Expenses	216.84	833.56	565.37	1,108.90	335.50
Operating Profit (EBIT)	-53.72	187.34	-80.49	235.00	65.30
Other Income	0.00	0.00	0.00	0.00	0.00
Profit before Tax	-59.52	203.83	-192.83	350.40	52.15
Provision for Tax	0.00	43.24	-4.79	128.00	10.61
Profit after Tax (Net Income)	-59.52	160.59	-188.05	222.40	41.54
Minority Interest	0.00	0.00	0.00	0.00	0.00
Consolidated Profit	0.00	93.19	0.00	0.00	0.00

Liabilities ($ Mln)

	Treace Medical Concepts (TMCI)	Penumbra (PEN)	Glaukos Corp (GKOS)	Bio-Rad Laboratories	Repligen (RGEN)
Shareholder's Funds	67.74	1,530.77	682.49	7,173.90	2,112.03
Minority Interest	0.00	0.00	0.00	0.00	0.00
Non-Current Liabilities	71.82	210.18	135.71	2,116.80	705.49
Current Liabilities	41.50	233.78	102.33	961.30	132.66
Total Liabilities	190.58	1,826.52	893.49	10,576.50	2,949.70

Assets ($ Mln)

	Treace Medical Concepts (TMCI)	Penumbra (PEN)	Glaukos Corp (GKOS)	Bio-Rad Laboratories	Repligen (RGEN)
Non-Current Assets	60.60	630.60	404.74	7,231.50	1,749.63
Current Assets	120.45	1,344.12	515.78	3,020.50	1,200.55
Total Assets	190.58	1,826.52	893.49	10,576.50	2,949.70
Total Debt*	72.69	212.71	102.84	1,203.70	690.94
Net Current Assets	78.96	1,110.35	413.45	2,059.20	1,067.90

Cashflow ($ Mln)

	Treace Medical Concepts (TMCI)	Penumbra (PEN)	Glaukos Corp (GKOS)	Bio-Rad Laboratories	Repligen (RGEN)
Cash From Operating Activities	-15.97	238.66	-46.34	532.20	117.42
Cash Flow from Investing Activities	13.25	-404.59	-77.61	-189.70	-298.47
Cash from Financing Activities	2.08	26.53	11.89	-283.20	-15.21
Net Cash Inflow / Outflow	--	--	--	--	--

Ratios

Profitability Ratios

	Treace Medical Concepts (TMCI)	Penumbra (PEN)	Glaukos Corp (GKOS)	Bio-Rad Laboratories	Repligen (RGEN)
ROCE (%)	-41.57	11.76	-22.53	8.98	1.79
ROE (%)	-76.76	10.86	-28.10	3.04	1.97
ROA (%)	-25.28	7.95	-18.00	2.02	1.36
EBIT Margin (%)	-26.15	13.63	-30.58	-5.99	9.87
Net Margin (%)	-28.99	10.67	-30.68	8.59	5.29
Cash Profit Margin (%)	0.00	0.00	0.00	0.00	0.00

Growth Ratios

	Treace Medical Concepts (TMCI)	Penumbra (PEN)	Glaukos Corp (GKOS)	Bio-Rad Laboratories	Repligen (RGEN)
Revenue Growth (%)	-3.95	17.55	41.55	1.37	16.49
EBIT Growth (%)	-22.25	17.49	-116.42	-131.06	920.91
Net Profit Growth (%)	-21.01	8.72	-102.66	-30.32	400.42
EPS Growth (%)	-17.90	8.12	-96.88	-29.66	394.30
Book Value Growth (%)	-32.79	17.33	-12.65	2.19	2.16

Valuation Ratios

	Treace Medical Concepts (TMCI)	Penumbra (PEN)	Glaukos Corp (GKOS)	Bio-Rad Laboratories	Repligen (RGEN)
Price / Earnings	-2.65	68.93	-34.59	--	189.42
Price / Book Value	1.79	8.31	15.27	--	4.40
Dividend Yield (%)	--	0.00	0.00	--	--
EV/EBITDA	-2.83	55.45	-73.80	--	55.90
Market Cap ($ Cr)	--	--	--	--	--

Solvency Ratios

	Treace Medical Concepts (TMCI)	Penumbra (PEN)	Glaukos Corp (GKOS)	Bio-Rad Laboratories	Repligen (RGEN)
Debt to Equity	0.83	0.00	0.00	0.11	0.26
Short term debt to equity ratio	0.05	0.01	0.00	0.06	0.01
Current Ratio	2.90	5.75	5.04	3.14	9.05
Quick Ratio	1.95	3.86	4.46	2.33	7.64
Interest Coverage	-9.23	157.91	-38.31	8.18	3.36

Operating Efficiency Ratios

	Treace Medical Concepts (TMCI)	Penumbra (PEN)	Glaukos Corp (GKOS)	Bio-Rad Laboratories	Repligen (RGEN)
Debtors to sales (%)	14.14	12.65	22.67	17.06	20.09
Asset Turnover	0.87	0.74	0.59	0.24	0.26
Receivable days	71.23	46.54	60.95	65.39	72.41
Inventory Days	320.21	331.92	193.84	221.09	146.53
Payable days	73.36	26.16	60.19	37.02	29.05
Cash Conversion Cycle	318.08	352.30	194.60	249.46	189.88

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Annual
Quarterly